GlassScriptPhysician profile
Salih Samo
NPI 1750643482
$251,160.84
in general payments reported to CMS, 2019-2025
21 companies · $97K in 2025
The $97K reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $111 · 2021: $802 · 2022: $1,876 · 2023: $14K · 2024: $136K · 2025: $97K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $196K · Travel and Lodging: $27K · Consulting Fee: $16K · Food and Beverage: $6,181 · Honoraria: $1,982 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $196,188.60 |
| Travel and Lodging | $26,775.46 |
| Consulting Fee | $16,290.00 |
| Food and Beverage | $6,180.95 |
| Honoraria | $1,981.50 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $105,166.11 | 2024-2025 | Eohilia |
| Phathom Pharmaceuticals, INC. | $96,470.07 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $16,092.57 | 2023-2025 | Gimoti |
| Genzyme Corporation | $11,008.73 | 2022-2025 | |
| Merit Medical Systems INC | $7,998.58 | 2025 | Esophyx |
| Endogastric Solutions, INC | $7,476.18 | 2019-2024 | Esophyx |
| Medtronic, INC. | $5,345.01 | 2021-2025 | Endoflip, Nexpowder, Pillcam |
| Cook Medical LLC | $793.75 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $184.35 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $122.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $99.64 | 2022 | |
| Boston Scientific Corporation | $85.99 | 2019 | |
| Covidien LP | $80.55 | 2020 | |
| Intuitive Surgical, INC. | $70.07 | 2021 | |
| Janssen Biotech, INC. | $44.85 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.18 | 2024 | Trulance |
| Abbvie INC. | $31.37 | 2021-2022 | |
| Qol Medical, LLC | $29.35 | 2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $17.73 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $7.77 | 2024 | Lockado |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salih Samo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.